|Bid||571.10 x 0|
|Ask||570.90 x 0|
|Day's range||555.20 - 571.40|
|52-week range||400.20 - 571.40|
|Beta (5Y monthly)||0.32|
|PE ratio (TTM)||31.03|
|Forward dividend & yield||9.10 (1.73%)|
|Ex-dividend date||26 Mar 2021|
|1y target est||N/A|
Novo Nordisk (NYSE: NVO) recently announced that it's buying Prothena's (NASDAQ: PRTA) transthetyrin amyloidosis (ATTR) cardiomyopathy program for up to $1.2 billion. In this Motley Fool Live video recorded on July 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why Novo, which is best known for its diabetes franchise, is buying a rare-disease drug candidate. There is a company, I don't know that we've talked about much, if at all in the past, Brian, Novo Nordisk.
Novo Nordisk (NVO) and Eli Lilly (LLY) announce small acquisition deals. J&J (JNJ) recalls some consumer products.
Prothena (PRTA) announces an agreement to sell its clinical-stage antibody, PRX004, and the broader ATTR amyloidosis program for $1.2 billion to Novo Nordisk.